Drug intelligence / Profile preview

iniparib + irinotecan

Development stage: Unknown
Lead developer: Sanofi
Modality: Small Molecules
Administration: Intravenous

Overview

Iniparib + irinotecan is a combination therapy investigated primarily for the treatment of advanced triple-negative breast cancer with brain metastases. Iniparib is a small molecule anti-cancer agent that alters reactive oxygen species tumor metabolism and can penetrate the blood-brain barrier. Irinotecan is a topoisomerase I inhibitor that interferes with DNA replication by stabilizing the topoisomerase I-DNA complex, leading to DNA damage and apoptosis of cancer cells. The combination has shown modest benefit in clinical trials for patients with progressive triple-negative breast cancer brain metastases, and both agents are administered intravenously[2][5][6].

Brand names: Camptosar (for irinotecan)

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on iniparib + irinotecan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iniparib + irinotecan.

Explore the full profile